Rene Goehrum Sells 1,522 Shares of BioSyent Inc. (CVE:RX) Stock

BioSyent Inc. (CVE:RX) Director Rene Goehrum sold 1,522 shares of BioSyent stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of C$9.38, for a total value of C$14,276.36.

BioSyent Price Performance

RX remained flat at C$9.51 during trading on Monday. The company’s stock had a trading volume of 3,430 shares, compared to its average volume of 6,612. The company’s 50 day moving average price is C$8.82 and its 200 day moving average price is C$8.72. The company has a quick ratio of 6.91, a current ratio of 6.48 and a debt-to-equity ratio of 3.51. BioSyent Inc. has a 52-week low of C$7.03 and a 52-week high of C$9.94. The company has a market capitalization of C$110.22 million, a PE ratio of 16.40 and a beta of 0.93.

BioSyent (CVE:RX) last issued its quarterly earnings data on Thursday, May 16th. The company reported C$0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of C$0.08 by C$0.07. The firm had revenue of C$7.73 million during the quarter, compared to the consensus estimate of C$7.90 million. BioSyent had a return on equity of 18.97% and a net margin of 20.45%. On average, sell-side analysts forecast that BioSyent Inc. will post 0.5544319 earnings per share for the current year.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.